GlassScriptPhysician profile
Jennifer Lin
NPI 1467404277
$7,385.63
in general payments reported to CMS, 2019-2025
31 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,687 · 2022: $1,392 · 2023: $1,525 · 2024: $699 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,306.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,068.21 | 2021-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $995.76 | 2022-2025 | |
| Novo Nordisk INC | $647.85 | 2021-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.18 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $466.61 | 2021-2023 | |
| Lilly USA, LLC | $292.31 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Kyowa Kirin, INC. | $248.31 | 2023-2025 | |
| Amgen INC. | $225.65 | 2021-2025 | Repatha, Tepezza |
| Sequel Med Tech, LLC | $192.46 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $179.09 | 2025 | Isturisa |
| Abbott Laboratories | $173.64 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Vivus LLC | $161.34 | 2025 | Pancreaze |
| Merck Sharp & Dohme LLC | $135.06 | 2023-2024 | Verquvo, Recarbrio, Dificid |
| Astellas Pharma US INC | $130.00 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $129.91 | 2021-2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $120.18 | 2024 | Uzedy |
| Travere Therapeutics, INC. | $120.12 | 2021 | |
| Corcept Therapeutics | $105.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.93 | 2024-2025 | |
| Madrigal Pharmaceuticals | $54.60 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $39.81 | 2025 | Unithroid |
| Pfizer INC. | $29.09 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.69 | 2024 | Spravato |
| Aimmune Therapeutics, INC. | $27.30 | 2025 | Zenpep |
| Amphastar Pharmaceuticals, INC. | $23.84 | 2025 | |
| Exact Sciences Corporation | $23.70 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $21.55 | 2025 | Gvoke Hypopen |
| Tolmar, INC. | $20.87 | 2025 | Jatenzo |
| Calliditas Therapeutics US INC. | $20.43 | 2024 | |
| Intra-Sana Laboratories | $18.37 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Phathom Pharmaceuticals, INC. | $17.99 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.